Fatty Liver Disease, Women, and Aldosterone: Finding a Link in the Jackson Heart Study
- PMID: 29264501
- PMCID: PMC5686785
- DOI: 10.1210/js.2017-00055
Fatty Liver Disease, Women, and Aldosterone: Finding a Link in the Jackson Heart Study
Abstract
Context: Fatty liver disease is one of the most common forms of chronic liver disease. The renin-angiotensin-aldosterone system has been implicated in the pathogenesis of fatty liver.
Objective: Determine the relationship between fatty liver and aldosterone in a large cohort study.
Design: Community-based, observational cohort study of African Americans.
Setting: The original Jackson Heart Study cohort enrolled African American participants from the Jackson, Mississippi, metropolitan area in Hinds, Madison, and Rankin Counties.
Participants: Our study population consisted of 2507 Jackson Heart Study participants (1625 women and 882 men) who had liver attenuation measured per computed tomography scans, had aldosterone measurements, and were not taking angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or mineralocorticoid receptor antagonists.
Intervention: There was no intervention.
Main outcome measure: Liver attenuation on computed tomography scans.
Results: Univariate regression analysis demonstrated a statistically significant correlation between aldosterone levels and liver attenuation. Each doubling of aldosterone was associated with 1.08 Hounsfield unit decrease (95% confidence interval, 1.47 to -0.69, P < 0.001). A multivariable model adjusted for body mass index, age, alcohol intake, and homeostatic model assessment of insulin resistance determined that the association was statistically significant only for women.
Conclusion: Our data demonstrate a positive association between aldosterone levels and fatty liver in African American women.
Keywords: aldosterone; fatty liver; women.
Figures
References
-
- Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):686–690. - PubMed
-
- Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010;52(1):79–104. - PubMed
-
- Abbas G, Silveira MG, Lindor KD. Hepatic fibrosis and the renin-angiotensin system. Am J Ther. 2011;18(6):e202–e208. - PubMed
-
- Toblli JE, Muñoz MC, Cao G, Mella J, Pereyra L, Mastai R. ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. Obesity (Silver Spring). 2007;16(4):770–776. - PubMed
-
- Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis. 2001;21(3):437–452. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources